A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China
Launched by ZHEJIANG UNIVERSITY · Jun 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The HERITAGE study is a clinical trial taking place in Zhejiang, China, aimed at helping older adults who are at risk of experiencing cognitive decline, which can lead to conditions like Alzheimer’s disease and dementia. The researchers want to see if a combination of lifestyle changes—such as increasing physical activity, improving nutrition, providing mental exercises, encouraging social interactions, and managing heart health—can help slow down cognitive decline in these individuals. This study will involve around 1,200 elderly residents over a period of two years.
To participate, individuals should be generally healthy but showing some signs of cognitive decline, meaning they have some difficulty with thinking and memory compared to others their age. They should not have any diagnosed dementia or other serious health conditions that could interfere with the study. Participants will be randomly assigned to either a group that receives the lifestyle intervention or a comparison group, and they will be expected to commit to all study activities for the full two years. This research could provide valuable insights into how lifestyle changes can support brain health in older adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At risk of cognitive decline: cognitive performance at the mean level or slightly lower than expected for age with no dementia (AD8\>=3 and/or 5-min MoCA \>, \< 11)
- • Free of physical disabilities that preclude participation in the study
- • Willing to complete all study-related activities for 24 months
- • Willing to be randomized to either lifestyle intervention group
- Exclusion Criteria:
- • Diagnosed dementia patients
- • Diagnosed major depression or other neuropsychological diseases
- • Malignant diseases
- • Symptomatic cardiovascular disease
- • Revascularization within one year
- • Severe loss of vision, hearing or communicative ability
About Zhejiang University
Zhejiang University is a prestigious research institution located in Hangzhou, China, renowned for its commitment to advancing medical science and healthcare innovation. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university plays a pivotal role in the development and execution of clinical trials aimed at improving patient outcomes and enhancing therapeutic approaches. Leveraging its extensive resources and expertise, Zhejiang University is dedicated to fostering advancements in medical knowledge while ensuring the highest standards of ethical conduct and scientific rigor in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported